Expression and significance of X chromosome linked inhibitor of apoptosis protein, high mobility group box-1 protein and Vimentin in gastric cancer

Objective To explore the expression and significance of X chromosome linked inhibitor of apoptosis protein (XIAP), high mobility group box-1 protein (HMGB1) and Vimentin in gastric cancer. Methods The expression levels of XIAP, HMGB1 and Vimentin in 84 cases of gastric cancer and adjacent normal tissues were detected by immunohistochemical in June 2016 to January 2019 in Hangzhou Dajiangdong Hospital, and the relationship between the expression of XIAP, HMGB1 and Vimentin and clinicopathological parameters was analyzed. Results The positive expression rate of XIAP in gastric cancer (65.48%, 55/84) was higher than that in adjacent normal tissues (17.86%, 15/84, χ2=50.837, P<0.05). The positive expression rate of HMGB1 in gastric cancer tissues (75.00%, 63/84) was higher than that in adjacent normal tissues (9.52%, 8/84, , χ2=73.791, P<0.05). The positive expression rate of Vimentin in gastric cancer tissues (70.23%, 59/84) was higher than that in adjacent normal tissues (20.24%, 17/84, χ2=42.384, P<0.05). The positive rate of XIAP, HMGB1 and Vimentin in stage Ⅲ-Ⅳ of gastric cancer was significantly higher than that in stage Ⅰ-Ⅱ (χ2=12.574, 9.821, P<0.05). The positive expression rate of XIAP, HMGB1 and Vimentin in patients with lymph node metastasis was significantly higher than that in patients without lymph node metastasis (χ2=23.290, 25.337, P<0.05). The positive rate of XIAP, HMGB1 and Vimentin in gastric cancer tissues were not correlated with age, sex and degree of differentiation. There was positive correlation between XIAP and HMGB1 (r=0.597, P<0.01), between XIAP and Vimentin (r=0.621, P<0.01), and between HMGB1 and Vimentin (r=0.634, P<0.01). Conclusion XIAP, HMGB1 and Vimentin were highly expressed in gastric cancer tissues, which could be used as predictors of the occurrence and malignancy of gastric cancer. Key words: X chromosome linked inhibitor of apoptosis protein; High mobility group box-1 protein; Vimentin; Gastric cancer